Our lead product MED2005, is a breakthrough topical glyceryl trinitrate (GTN) gel for erectile dysfunction (ED) currently in Phase 3 clinical trials.

Thanks to our proprietary drug delivery technology platform DermaSys®, MED2005 will be a strongly differentiated and innovative product addressing unmet needs in the ED market.

Click on the circle icons to view more information about each section.

Works rapidly

MED2005 has the potential to have the fastest speed of onset for any erectile dysfunction treatment

Enables spontaneity

MED2005 removes the need for planning of sex associated with some oral PDE5i medications

Restores intimacy

MED2005’s direct mode of application can form part of foreplay and combined with its speed of onset can help restore intimacy.

Well tolerated

MED2005 is well tolerated, with a lower potential than oral PDE5i inhibitors for systemic side effects.

The treatment of ED has not seen any new clinical products for 1-2 decades. MED2005 is a novel glyceryl trinitrate (GTN) topical gel with an enhanced absorption delivery system. After application to the glans penis, there is a rapid onset of action (5-10 mins in 70% of spontaneous attempts at intercourse) in contrast to current oral PDE5i's, which take 30-90 mins to act. This novel topical therapy is easy to use, does not have any food or alcohol interactions, and has excellent tolerability for both patient and partner.

"I am excited to be part of an advisory panel helping to shape the future program for MED2005 as it enters Phase 3 studies, and I look forward to ultimate approval by the FDA and regulators around the world. It offers new hope to patients who, for whatever reason, are dissatisfied with current therapies or are precluded from their use.

Professor Wayne Hellstrom

Professor of Urology and Chief of Andrology

Tulane University School of Medicine, New Orleans, US

Past President of the International Society of Sexual Medicine